rs1800795
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Most associations varied by recent aspirin/NSAID use: IL6 rs1800796 and rs1800795 polymorphisms were associated inversely with tumor mutations in the presence of aspirin/NSAIDs; POMC significantly reduced risk of Ki-ras-mutated tumors when aspirin/NSAIDs were not used; the TCF7L2 rs7903146 was associated with reduced risk of Ki-ras-mutated tumors in the presence of aspirin and increased risk in the absence of aspirin.
|
18992263 |
2009 |
rs1800795
|
|
|
0.050 |
GeneticVariation |
BEFREE |
There were no significant relationships between rs1800795 status and any patient or tumor characteristics, including estrogen receptor status.
|
28732081 |
2017 |
rs1800795
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We assessed how these tumor markers were associated with use of anti-inflammatory drugs, polymorphisms in the IL6 genes (rs1800795 and rs1800796) and dietary antioxidants.
|
19452524 |
2009 |
rs1800795
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The rs1800795 polymorphism in the promoter of the gene IL-6 can affect the transcription and expression of the gene, becoming a common target in association studies on tumors.
|
28296724 |
2017 |
rs1800795
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Associations between potentially functional IL6 (rs2069837 and rs1800795) and STAT3 (rs744166 and rs4796793) SNPs and clinical outcomes [progression-free survival (PFS), overall survival, and tumor response rate] were evaluated in mCRC patients receiving first-line FOLFIRI plus bevacizumab in two randomized phase III trials: TRIBE (n = 223, training cohort) and FIRE-3 (n = 288, validation cohort).
|
26839145 |
2016 |
rs1800796
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We assessed how these tumor markers were associated with use of anti-inflammatory drugs, polymorphisms in the IL6 genes (rs1800795 and rs1800796) and dietary antioxidants.
|
19452524 |
2009 |
rs1800796
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Most associations varied by recent aspirin/NSAID use: IL6 rs1800796 and rs1800795 polymorphisms were associated inversely with tumor mutations in the presence of aspirin/NSAIDs; POMC significantly reduced risk of Ki-ras-mutated tumors when aspirin/NSAIDs were not used; the TCF7L2 rs7903146 was associated with reduced risk of Ki-ras-mutated tumors in the presence of aspirin and increased risk in the absence of aspirin.
|
18992263 |
2009 |
rs1800797
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Considering these promising results, IL-6 promoter including rs1800795, rs1800796 and rs1800797 may be a tumor marker for cancer therapy.
|
29552316 |
2018 |
rs2069837
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Associations between potentially functional IL6 (rs2069837 and rs1800795) and STAT3 (rs744166 and rs4796793) SNPs and clinical outcomes [progression-free survival (PFS), overall survival, and tumor response rate] were evaluated in mCRC patients receiving first-line FOLFIRI plus bevacizumab in two randomized phase III trials: TRIBE (n = 223, training cohort) and FIRE-3 (n = 288, validation cohort).
|
26839145 |
2016 |